Haematologica, 0390-6078


View graph of relations

Related Publications
  1. Bortezomib based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial

    Minnema, M. C., Nasserinejad, K., Hazenberg, B., Hegenbart, U., Vlummens, P., Ypma, P. F., Kröger, N., Wu, K. L., Kersten, M. J., Schaafsma, M. R., Croockewit, S., de Waal, E., Zweegman, S., Tick, L., Broijl, A., Koene, H., Bos, G., Sonneveld, P. & Schönland, S., 2019, In : Haematologica.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

    Broijl, A., Kersten, M. J., Alemayehu, W. G., Levin, M. D., de Weerdt, O., Vellenga, E., Meijer, E., Wittebol, S., Tanis, B. C., Cornelisse, P. B., Stevens-Kroef, M., Bos, G. M. J., Wijermans, P. W., Lokhorst, H. & Sonneveld, P., 31-Mar-2016, In : Haematologica. 101, 4, p. e149-e152

    Research output: Contribution to journalLetterAcademicpeer-review

  3. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis

    CAT-prediction Collaborators, Mulder, F. I., Candeloro, M., Kamphuisen, P. W., Di Nisio, M., Bossuyt, P. M., Guman, N., Smit, K., Buller, H. R. & van Es, N., 31-May-2019, In : Haematologica. 104, 6, p. 1277-1287 11 p.

    Research output: Contribution to journalReview articleAcademicpeer-review

  4. MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavourable prognosis

    Vermaat, J. S., Somers, S. F., de Wreede, L. C., Kraan, W., de Groen, R. A. L., Schrader, A. M. R., Kerver, E. D., Scheepstra, C. G., Beerenschot, H., Deenik, W., Wegman, J., Broers, R., de Boer, J-P. D., Nijland, M., van Wezel, T., Veelken, H., Spaargaren, M., Cleven, A. H., Kersten, M. J. & Pals, S. T., 2019, In : Haematologica. 33 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial

    Wester, R., van der Holt, B., Asselbergs, E., Zweegman, S., Kersten, M. J., Vellenga, E., van Marwijk Kooy, M., de Weerdt, O., Minnema, M., Lonergan, S., Palumbo, A., Lokhorst, H., Broijl, A. & Sonneveld, P., 4-Apr-2019, In : Haematologica. 29 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (121) »

ID: 1556195